No significant differences were found between CHEK2 H371Y carriers and non-carriers with regard to tumor size, lymph node status, ER or PR status, chemotherapy regimens, surgery type, tumor grade, and pathological type (Table 1). Here, CHEK2 is linked to neoplasm.